IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF-κB– and caspase-8–dependent mechanisms
Liang Zhou,Yu Zhang,Mark B Meads,Yun Dai,Yanxia Ning,Xiaoyan Hu,Lin Li,Kanika Sharma,Jewel Nkwocha,Rebecca Parker,Danny Bui,Jacquelyn McCarter,Lora Kramer,Cullen Purcell,Praneeth Sudalagunta,Rafael Renatino Canevarolo,Maria D Coelho Siqueira Silva,Gabriel DeAvila,Raghunandan Reddy Alugubelli,Ariosto Siqueira Silva,Maciej Kmieciak,Andrea Ferreira-Gonzalez,Kenneth H Shain,Steven Grant,Mark B. Meads,Praneeth R. Sudalagunta,Rafael R. Canevarolo,Maria D. Coelho Siqueira Silva,Gabriel De Avila,Ariosto S. Silva,Maciej Kmeiciak,Kenneth H. Shain
DOI: https://doi.org/10.1182/bloodadvances.2020003597
IF: 7.642
2021-08-31
Blood Advances
Abstract:Abstract Interactions between the inhibitor of apoptosis protein antagonist LCL161 and the histone deacetylase inhibitor panobinostat (LBH589) were examined in human multiple myeloma (MM) cells. LCL161 and panobinostat interacted synergistically to induce apoptosis in diverse MM cell lines, including those resistant to bortezomib (PS-R). Similar interactions were observed with other histone deacetylase inhibitors (MS-275) or inhibitors of apoptosis protein antagonists (birinapant). These events were associated with downregulation of the noncanonical (but not the canonical) NF-κB pathway and activation of the extrinsic, caspase-8–related apoptotic cascade. Coexposure of MM cells to LCL161/LBH589 induced TRAF3 upregulation and led to TRAF2 and NIK downregulation, diminished expression of BCL-XL, and induction of γH2A.X. Ectopic expression of TRAF2, NIK, or BCL-XL, or short hairpin RNA TRAF3 knock-down, significantly reduced LCL161/LBH589 lethality, as did ectopic expression of dominant-negative FADD. Stromal/microenvironmental factors failed to diminish LCL161/LBH589–induced cell death. The LCL161/LBH589 regimen significantly increased cell killing in primary CD138+ cells (N = 31) and was particularly effective in diminishing the primitive progenitor cell–enriched CD138–/19+/20+/27+ population (N = 23) but was nontoxic to normal CD34+ cells. Finally, combined LCL161/LBH589 treatment significantly increased survival compared with single-agent treatment in an immunocompetent 5TGM1 murine MM model. Together, these findings argue that LCL161 interacts synergistically with LBH589 in MM cells through a process involving inactivation of the noncanonical NF-κB pathway and activation of the extrinsic apoptotic pathway, upregulation of TRAF3, and downregulation of TRAF2/BCL-XL. Notably, this regimen overcomes various forms of resistance, is active against primary MM cells, and displays significant in vivo activity. This strategy warrants further consideration in MM.
hematology